Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright

Ocular Therapeutix (NASDAQ:OCUL - Free Report) had its price target increased by HC Wainwright from $14.00 to $15.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company's stock.

Several other equities analysts have also recently commented on the stock. Scotiabank started coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 price target on the stock. Robert W. Baird lowered their price target on shares of Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Ocular Therapeutix presently has an average rating of "Moderate Buy" and an average target price of $16.71.

Ocular Therapeutix Stock Down 7.7 %

Shares of Ocular Therapeutix stock traded down $0.76 on Friday, hitting $9.16. 1,298,696 shares of the company traded hands, compared to its average volume of 1,860,444. The company has a 50-day moving average price of $9.83 and a 200 day moving average price of $7.96. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. Ocular Therapeutix has a 12-month low of $2.05 and a 12-month high of $11.77. The company has a market cap of $1.43 billion, a PE ratio of -7.35 and a beta of 1.26.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OCUL. Atlas Capital Advisors LLC acquired a new position in Ocular Therapeutix during the 2nd quarter worth $34,000. Amalgamated Bank raised its position in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 1,015 shares during the last quarter. Algert Global LLC acquired a new position in shares of Ocular Therapeutix during the second quarter valued at about $69,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Ocular Therapeutix during the third quarter valued at about $70,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.